Earnings Releases·Oct 27, 2026, 4:07 PM ET

OrthoPediatrics Corp. — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached a record $72.7 million, up 19% YoY, while net loss narrowed to $5.9 million ($0.25/share) from $11.8 million in the prior year period; adjusted EBITDA rose to a record $6.9 million and free cash flow improved by $5.0 million to $1.6 million.
Full-year 2026 revenue guidance was raised to $270.0 million–$273.0 million (14%–16% growth), with adjusted EBITDA expected at $25.0 million and annual breakeven free cash flow anticipated.
Growth was driven by 19% YoY increases in Trauma & Deformity and Scoliosis segments, alongside market share gains and the full market release of the 3P Pediatric Plating Platform Hip System.
Total liabilities increased to $169.7 million and cash balances declined to $44.9 million due to clinic expansions, small-scale acquisitions, and higher operating expenses, while a $0.6 million intangible asset impairment was recorded.